Health & Wellness

Overlook Medical Center expert part of new clinical study for Tourette Syndrome

February 15, 2014 at 6:31 AM

SUMMIT – Medical researchers are hopeful that a new investigational drug being tested in clinical trials will prove to be an effective treatment for Tourette Syndrome – an inherited, misdiagnosed, misunderstood neurological disorder that presents in childhood and causes involuntary motor and vocal tics.

The new drug, AZD5213, targets the human histamine H3 receptor.  In the brain, this receptor regulates neurotransmitters associated with Tourette Syndrome – including dopamine and histamine. A mutation that affects histamine synthesis was recently confirmed to be the cause of TS in a father and all eight of his children, a finding supported by research in mice.

If approved for treatment of Tourette, AZD5213 might represent an alternative to antipsychotics, which don’t work well in all patients and can cause serious negative side effects.  Discovered by AstraZeneca, AZD5213 has been shown to have a favorable safety profile, with no serious drug-related side effects reported in Phase 1 and Phase 2 clinical trials completed at the time of this report.

Sign Up for E-News

”AZD5213 represents an exciting new approach to the treatment of Tourette Syndrome, and we are currently recruiting teenagers suffering from the disorder to participate in the clinical trial,” says Dr. Roger Kurlan, Director of the Movement Disorders Program at Overlook Medical Center’s Atlantic Neuroscience Institute in Summit, N.J.

Dr. Kurlan, who frequently collaborates with the NJ Center for Tourette Syndrome & Associated Disorders (NJCTS) in Somerville, N.J., is a leading expert in the treatment of Tourette and is one of approximately six medical researchers involved in the clinical trial.

AZD5213 already has been studied in other clinical trials, including those for Alzheimer’s disease. With Tourette Syndrome, which is associated with changes in brain chemistry that appear to cause the characteristic symptoms of the disorder, AZD5213 might be able to counteract these changes – with the potential to provide symptomatic relief with less of the negative side effects associated with existing treatments.  More than 200 human subjects have already received single or multiple doses of AZD5213, with no serious drug-related adverse side effects.

According to the Centers for Disease Control and Prevention (CDC), 1 in 100 children show signs of Tourette Syndrome. The disorder is three times as likely in boys as in girls, and most patients experience their worst symptoms in their early teen years. There is no cure, and symptoms can persist throughout life – although most patients see improvement as they approach and enter adulthood.

Exaggerated portrayals of Tourette Syndrome have been used for comic relief in films and TV shows, usually featuring characters who shout obscenities involuntarily. In reality, this type of verbal tic – known as coprolalia – is present in only 10 to 15 percent of those with TS.

“In real life, Tourette’s is no laughing matter,” Dr. Kurlan says. “These patients often struggle with self-esteem and socialization issues, which generally arise at a crucial time in their social development.  Sadly, many are victims of bullying and the ridicule of their peers.”

Tourette’s is most often present in combination with other neurological disorders, such as attention deficit-hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD), and Tourette’s patients are commonly troubled by depression, anxiety and developmental delays.

For more information about this Tourette Syndrome trial or to participate in it, please call 908-522-5901 or e-mail caroline.panter@atlantichealth.org. More information about TS and the work being done statewide by the NJ Center for Tourette Syndrome is available by calling 908-575-7350 or by visiting www.njcts.org.

TAP Into Another Town's News:

TAP Into Another Town's News:

Sign Up for E-News

Summit

Every Little Bit Helps

January 17, 2017

Trenton lawmakers postponed their vote on S2855 the “Electronic Publication of Legal Notices Act”. This bill would end the mandate for municipalities to publicly advertise legal notices in print newspapers. S2855 would allow municipalities to publish legal notices on their own websites or have them published online by a third party.

How much would this bill save ...

Upcoming Events

Carousel_image_a907f7dda0a18ad92d97_aqua_boot_camp

Wed, January 18, 9:30 AM

The Connection, Summit

Aqua Boot Camp

Arts & Entertainment Health & Wellness

Carousel_image_48d23eb86351e2d19b2e_1cc0c318b3b034e1e033_winter_storytime

Wed, January 18, 10:00 AM

Summit Free Public Library, Summit

Storytime

Community Calendar Education

Carousel_image_ddb615667c17d33439d1_cc08308976910c1bffc6_citizenship

Wed, January 18, 11:00 AM

Summit Public Library , Summit

Citizenship Study Group Practice for the Test

Education Government

Summit Fire Department Blotter

Dec. 1, 2016 0233 - Units responded to a motor vehicle accident with injuries and an overturned vehicle with possible extrication. Incident located at mm 10 Route 24, West.  Springfield and Millburn FD also on scene.  Summit provided a safety block, and for scene safety and assisted with securing vehicles.  

Dec. 5, 2016 at 12:25 - Units dispatched to a PARK AVE apartment for a ...

Summit Police Blotter

January 9, 2017

12/24 - Nelson Collazo-Moreno, 25, of Summit was arrested for driving while intoxicated. Mr. Moreno was released with a pending court date.

01/01 - At 1323 hours a report was taken for a theft from a Springfield Avenue apartment complex. The maroon colored “Exit” sign had been removed sometime between 1800 hours on 12/31/16 and 1300 hours on 01/01/17. The approximate value of ...

Summer Camp Open House at The Connection Set for Jan. 22

January 17, 2017

Choosing a camp is an important decision for families to make, but it doesn’t need to be a difficult one. To help make the decision easier, The Connection is offering a Summer Camp Open House on Sunday, January 22 from 1:30-3:30pm to introduce their exciting changes for summer 2017. Stop by and let the kids experience the “Camp Sampler” including camp activities, free swim ...

Audio: Point View's Petrides Tells Bloomberg Says Content Move Makes Sense for Apple

Point View's Managing Director and Portfolio Manager, John Petrides, spoke live on Bloomberg Radio (Interview starts at 1:35) discussing Apple's potential move into making original video content:

assets.bwbx.io

Point View Wealth Management, Inc. works with families in Summit and beyond, providing customized portfolio management services and ...

Today’s Bond Market - Should I Stay or Should I Go?

2016’s final days left bond investors unsettled.

Just a few months ago, with the backdrop of the surprise July Brexit vote, U.S. Treasury yields hit record lows. Donald Trump’s election as president has increased concerns of a new round of tax cuts and greater government spending, which could stimulate inflation. The Federal Reserve has finally raised interest rates and is ...

Now We're Cooking: Culinary Creations Cater to On-Site Business Needs

The emergence of small and mid-size companies moving into the Summit has been impressive. Along with a number of townhome developments that have sprung up in the heart of the downtown in this and other surrounding affluent towns, have come satellite offices of some of Manhattan’s most influential firms.

Mixed in with these offices are a number of smaller companies that have taken flight ...

Man vs. Waze

A lot of strange cars are traveling through my quiet neighborhood these days.  They are not driven by my neighbors.  Some mornings I even have trouble getting out of my driveway.  

Waze.

Ever since bridge repair closed a major thoroughfare near my house, the traffic on my sleepy street has increased dramatically.  And it is not by accident that commuters have figured out ...